Northrop Grumman heads into its July 23 earnings report with the Street broadly bullish but visibly less confident — a gap between consensus targets and the current price that tells the real story this week.
The analyst picture is the clearest tension here. The mean price target is $696.95, implying roughly 27% upside from Monday's close of $548.67 — a spread that sounds compelling until you trace how that average has been built. The trend has been one of near-uniform target cuts. Jefferies trimmed to $620 from $660 in late May while staying at Hold. Citigroup lowered its Buy target to $628 from $742 over the same stretch. Morgan Stanley, UBS, and others cut after Q1 results in April. The direction is consistent: analysts still believe in the name, but they're ratcheting down their near-term numbers. The mean target is being carried by a few outliers — BTIG's $815 and UBS's $745 — while the cluster around $620–$630 reflects a more cautious consensus floor. Wells Fargo's April initiation at $800 with an Overweight looks increasingly like an outlier read rather than a baseline.
The bull case rests on Northrop's role in long-duration DoD programs — particularly the B-21 bomber — strong free cash flow generation, and expanding international sales. Bears point to budgetary pressures slowing near-term sales growth, incremental capex weighing on cash conversion, and program realignment risk. Factor scores add texture to that debate: the EV/EBIT rank at the 65th percentile suggests the valuation is not stretched, but EPS momentum is weak — sitting at just the 28th percentile on a 30-day basis and the 39th percentile over 90 days. Forward earnings revisions have been negative (the 12-month forward EPS growth rank is near the bottom of the universe at just the 2nd percentile), which squares with why analysts are cutting targets even while maintaining Buy ratings. One standout in the factor data is the dividend score at the 99th percentile, though the dividend history in this snapshot appears stale and should be treated with caution.
Short positioning offers no real drama. Short interest is just 1.26% of the free float and falling — down roughly 17% on the week to around 1.79 million shares. Borrow conditions are completely unencumbered: availability is effectively unlimited, with more than 130 million shares available to lend relative to the tiny short base. Cost to borrow is negligible at 0.29%, down sharply from above 0.5% in early May. This is not a name where short sellers are making a directional bet. The short score of 29.7 out of 100 confirms as much — shorts are a non-factor in the current setup. Options positioning is similarly relaxed: the put/call ratio of 0.90 is slightly below its 20-day average of 0.92, and the z-score of -0.33 puts it comfortably inside normal range. Neither the shorts nor the options market is expressing unusual caution.
The earnings reaction history is worth noting. The April 21 Q1 print saw NOC fall 10.3% on the day and 12% over the following week — a significant negative response that appears to have reset analyst assumptions and triggered the round of target cuts. The May 20 event (likely a separate update) produced only a -0.9% move, suggesting some of the bad news was already absorbed. Peers have generally moved in the same direction this week — RTX up 4.2% on the week, LMT up 3.3% — with NOC's 2.3% gain modestly lagging that group. LHX essentially flatlined on the week at +0.02%, so NOC's relative position is somewhere in the middle of the defense pack.
The July 23 print is the focal point from here. With EPS momentum deteriorating, targets clustered well above where the stock trades, and Q1 still fresh in memory as a painful miss, the debate will centre less on whether Northrop's programs are intact and more on whether management can demonstrate that the April selloff was an overreaction — or confirm that near-term guidance genuinely needs to come down further.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
